Sun Life and Medzown team up to expand access to clinical trials for cancer and other complex diseases

Rhea-AI Summary

Sun Life (SLF) and Medzown are partnering to expand access to clinical trials for employees at self-funded employers across the U.S. The collaboration uses Medzown's AI-powered clinical model to identify members with cancer and other complex conditions and connect them to advanced therapies and trials.

According to Sun Life, cancer costs average $252,000 per individual annually and ortho/MSK conditions $120,000. Medzown becomes part of Sun Life's Health and Risk Solutions suite, aimed at improving outcomes while helping employers manage high-cost medical and specialty drug claims.

Positive

• Medzown collaboration adds AI-powered clinical trial access to Sun Life stop-loss clients
• Targets high-cost cancer and ortho/MSK claims averaging $252,000 and $120,000 per member
• Enhances Sun Life Health and Risk Solutions with precision medicine and navigation support

Negative

• None.

News Market Reaction – SLF

+0.36%

+0.36% Session close to close

In the Jun 17 session, SLF gained 0.36%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds a precision-medicine partnership to Sun Life’s Health and Risk Solutions, foc...

Analysis

This announcement adds a precision-medicine partnership to Sun Life’s Health and Risk Solutions, focusing on cancer and ortho/MSK cases that average $252,000 and $120,000 per person annually. It builds on recent work analyzing high-cost claims among self-funded employers. Investors may track uptake among stop-loss clients, measurable impacts on high-dollar claims, and how this initiative complements existing offerings like Clinical 360 and Expert Cancer Review.

Key Figures

Average annual cancer cost: $252,000 per individual per year Average annual ortho/MSK cost: $120,000 per individual per year

2 metrics

Average annual cancer cost $252,000 per individual per year Sun Life 2026 high-cost claims report

Average annual ortho/MSK cost $120,000 per individual per year Sun Life 2026 high-cost claims report

Historical Context

5 past events · Latest: Jun 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 10	Distribution partnership	Positive	+1.3%	Added to Centro’s API RFP platform to streamline benefits distribution.
Jun 04	Community investment	Positive	+1.2%	HELP Hero award tied to $90M shelter investment and $25K donation.
May 26	NCIB renewal	Positive	-0.6%	Approval to repurchase up to 10M shares over one year.
May 21	Claims analysis report	Neutral	-0.2%	Release of high-cost claims and injectable drug trends study.
May 07	Director elections	Neutral	+0.8%	All 13 director nominees elected with very high support levels.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has been mostly strategic and governance-focused, with positive or neutral items often seeing modestly positive price reactions, while the NCIB renewal saw a small divergence.

Recent Company History

Over the last few months, Sun Life has reported several corporate and strategic milestones. In May 2026, it renewed a normal course issuer bid for up to 10,000,000 shares, following fully using the prior bid, though shares eased 0.58% after that news. Other updates, including director elections, a high-cost claims report on complex medical conditions, and being added to Centro’s API-powered RFP platform, generally saw mild positive reactions. The new Medzown collaboration builds on this health and benefits-focused trajectory in the U.S. stop-loss market.

Key Terms

clinical trials, precision medicine, stop-loss insurance, self-funded employers, +4 more

8 terms

clinical trials medical

"increase access to clinical trials for employees at self-insured employers"

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

precision medicine medical

"Medzown, Inc., a precision medicine management company"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

stop-loss insurance financial

"Sun Life stop-loss insurance is an invaluable safety net for self-funded employers"

Stop-loss insurance is a policy that kicks in when losses from a specific risk exceed a pre-set threshold, reimbursing the policyholder for the amount above that limit. Think of it as a safety net or umbrella that prevents a single large bill from wiping out a budget; investors watch for it because it reduces a company’s exposure to sudden, outsized costs and therefore lowers the chance of unexpected hits to profit, cash flow, and balance-sheet stability.

self-funded employers financial

"clinical trials for employees at self-insured employers across the country"

Self-funded employers pay employee health care claims themselves instead of buying a traditional group insurance policy, often hiring a third-party administrator to process bills and sometimes buying insurance to limit very large losses. For investors, this choice affects a company’s cash flow and exposure to unpredictable health costs — like a homeowner skipping an extended warranty to save money but taking on the risk of a big, unexpected repair — which can influence earnings volatility and balance-sheet risk.

specialty drug medical

"reducing specialty drug cost exposure and delivering measurable results"

Drugs used to treat complex, chronic, or rare medical conditions that often require special storage, administration, or monitoring and typically cost much more than ordinary medicines. For investors, specialty drugs matter because they can generate high revenue per patient and stronger pricing power—like a custom-tailored product versus an off-the-rack item—but also carry greater regulatory, reimbursement, and supply risks that can affect a company’s earnings.

high-cost claims financial

"another touch point to address high-cost claims before they escalate"

High-cost claims are individual insurance claims with unusually large payouts, such as major surgeries, long-term treatments, or catastrophic losses that are far higher than typical claims. For investors, they matter because a few very large bills can drive unexpected losses, force insurers to raise reserves or premiums, and create volatility in earnings much like a single large repair can upend a household budget.

AI-powered clinical model technical

"leverage Medzown's AI-powered clinical model to identify patients"

An ai-powered clinical model is a computer-based system that uses machine learning to analyze medical data and predict patient outcomes, diagnose conditions, or guide treatment and trial decisions. It matters to investors because it can shorten development time, lower costs and increase the chance a drug or device succeeds by helping researchers pick the right patients and predict results more reliably—like a weather forecast for clinical trials that aims to reduce surprises and wasted effort.

Predictive Population Analytics technical

"Medzown's Predictive Population Analytics platform proactively recognizes members"

Predictive population analytics uses large sets of anonymized health, behavior and demographic data plus statistical models to forecast how groups of people are likely to get sick, use services, or respond to treatments. For investors it reveals potential market size, cost trends, and risks for healthcare providers, insurers and product makers—think of it as a weather forecast for a population that helps firms plan capacity, pricing and product demand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The collaboration advances shared goals of improving members' health outcomes while reducing specialty drug cost exposure and delivering measurable results for self-funded employers

BOSTON and WELLESLEY, Mass., June 16, 2026 /PRNewswire/ -- Sun Life U.S., the nation's largest independent stop-loss provider, and Medzown, Inc., a precision medicine management company, are collaborating to increase access to clinical trials for employees at self-insured employers across the country. Medzown improves access to advanced therapies and clinical trials for patients with cancer and other complex conditions, such as orthopedic/musculoskeletal (ortho/MSK). New and existing Sun Life stop-loss clients will have the opportunity to leverage Medzown's AI-powered clinical model to identify patients at a diagnostic or therapeutic crossroads and connect them to an appropriate clinical trial. This offers another touch point to address high-cost claims before they escalate, an increasingly common pattern with complex health conditions. Medzown is the latest addition to Sun Life's comprehensive suite of health solutions designed to improve health outcomes for members and drive down costs for clients.

According to Sun Life's 2026 high-cost claims report, which analyzes drug treatment, healthcare and high-dollar medical claim trends, cancer costs an average of $252,000 per individual per year, while ortho/MSK costs an average of $120,000. Medzown's Predictive Population Analytics platform proactively recognizes members with rare diseases, oncology diagnoses and other complex conditions who may benefit from advanced treatment options, including enrollment in clinical trials.

"Sun Life stop-loss insurance is an invaluable safety net for self-funded employers to mitigate the financial impact of high-cost claims," said Dr. Jennifer Levin Carter, founder and CEO of Medzown. "Medzown's precision medicine capabilities extend that safety net to ensure members navigating a cancer diagnosis or rare disease have access to every medical intervention available. Together, we can offer a comprehensive solution for employers actively seeking smarter approaches to improve health outcomes, contain high-cost claims and ensure every patient has the support they need to manage a life-changing diagnosis."

Medzown's proprietary approach prioritizes member engagement through cobranded outreach with the employer client. A team of precision medicine scientists and personal navigators work directly with patients and their care teams, serving as a seamless extension of existing member benefits. They ensure that every eligible member has a clear, supported path to the most appropriate therapy — including cutting-edge treatments that may reduce long-term specialty drug costs for employers.

"Employers who self-fund their health plans face immense financial risk when members develop complex, costly conditions," said Jennifer Collier, president, Health and Risk Solutions, Sun Life U.S. "Medzown's clinical expertise and individualized support is uniquely suited to address both the human and financial sides of managing major health conditions. There are many approaches we offer for improving health outcomes and reducing medical spend; adding access to clinical trials is an important next step in ensuring our clients can offer their employees the best opportunities for effective care."  

Sun Life U.S. is the largest independent medical stop-loss provider in the country. In addition to stop-loss, Sun Life offers self-funded employers unique health services and solution touchpoints that help people access care and experience improved health outcomes, while also reducing the risk of high-dollar claims.

Sun Life's Health and Risk Solutions include:

• Clinical 360 (Expert clinical review of high-dollar claims to identify opportunities for cost reduction)
• Health Navigator (1:1 care navigation services)
• Expert Cancer Review (Access to expert second opinions)
• Additional health support for those with ortho/MSK conditions

For more information about Sun Life's stop-loss solutions, visit www.sunlife.com/us. For information about Medzown's precision medicine management capabilities, visit medzown.com.

About Sun Life
Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2026, Sun Life had total assets under management of C$1.58 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Sun Life U.S. is one of the largest providers of employee and government benefits, helping approximately 48 million Americans access the care and coverage they need. Through employers, industry partners and government programs, Sun Life U.S. offers a portfolio of benefits and services, including dental, vision, disability, absence management, life, supplemental health, medical stop-loss insurance, and healthcare navigation. Sun Life employs nearly 8,300 people in the U.S., including associates in our partner dental practices and affiliated companies in asset management. Group insurance policies are issued by Sun Life Assurance Company of Canada (Wellesley Hills, Mass.), except in New York, where policies are issued by Sun Life and Health Insurance Company (U.S.) (Lansing, Mich.). For more information visit our website and newsroom.

About Medzown
Medzown is a precision medicine management company dedicated to expanding access to advanced therapies and clinical trials for patients with cancer and other high-cost, complex diseases. Founded in 2022 by clinician and entrepreneur Dr. Jennifer Levin Carter, Medzown combines advanced data analytics with expert clinical guidance to help patients receive the most effective, individualized care while enabling employers and payers to better manage rising specialty drug costs. Medzown's platform integrates molecular, clinical, and claims data to match patients with appropriate therapies and clinical trials, with each case reviewed by PhD scientists and supported by personal navigators who work directly with patients and their physicians. Learn more at Medzown.com.

Media Contacts

Devon Fernald
Sun Life U.S.
devon.portney.fernald@sunlife.com

Josh Birch
Medzown
josh.birch@medzown.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sun-life-and-medzown-team-up-to-expand-access-to-clinical-trials-for-cancer-and-other-complex-diseases-302802316.html

SOURCE Sun Life U.S.

FAQ

What did Sun Life (SLF) announce on June 16, 2026 about its partnership with Medzown?

Sun Life announced a collaboration with Medzown to expand access to clinical trials for employees of self-funded employers. According to Sun Life, Medzown’s AI-powered platform will help identify members with complex conditions and connect them with suitable advanced therapies and clinical trials nationwide.

How will the Sun Life and Medzown collaboration expand access to cancer clinical trials for self-funded employers?

The collaboration will use Medzown’s AI-powered clinical model to flag members at diagnostic or therapeutic crossroads. According to Sun Life, eligible patients with cancer and other complex diseases can then be guided toward appropriate clinical trials and advanced therapies through Medzown’s precision medicine team and navigators.

Which high-cost conditions does the Sun Life (SLF) and Medzown partnership aim to address?

The partnership focuses on cancer, rare diseases and orthopedic/musculoskeletal (ortho/MSK) and other complex conditions. According to Sun Life, cancer costs average $252,000 per individual annually and ortho/MSK $120,000, making these key targets for improved care access and high-cost claim management.

How could the Sun Life and Medzown partnership help reduce specialty drug and medical costs for employers?

The partnership aims to intervene before claims escalate by matching eligible members with appropriate therapies and clinical trials. According to Sun Life, earlier, better-targeted interventions may help manage long-term specialty drug spending and high-dollar medical claims for self-funded employer health plans.

What role does Medzown’s Predictive Population Analytics platform play in the Sun Life (SLF) collaboration?

Medzown’s Predictive Population Analytics platform proactively identifies members with rare diseases, oncology diagnoses and complex conditions. According to Sun Life, these members may benefit from advanced treatment options, including enrollment in clinical trials, supported by precision medicine scientists and personal navigators.

How does the Medzown partnership fit within Sun Life’s Health and Risk Solutions for self-funded employers?

Medzown becomes part of Sun Life’s Health and Risk Solutions suite, alongside Clinical 360, Health Navigator and Expert Cancer Review. According to Sun Life, adding clinical trial access offers another touch point to improve member outcomes and reduce the risk of high-dollar claims.